• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines

Introduction to Morpholine, 4-(3S)-3-pyrrolidinyl- (CAS No. 216669-67-9)

Morpholine, 4-(3S)-3-pyrrolidinyl- (CAS No. 216669-67-9) is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential biological activities. This compound belongs to the class of morpholines, which are widely used as building blocks in the synthesis of various bioactive molecules and drug candidates.

The chiral center at the pyrrolidine moiety of Morpholine, 4-(3S)-3-pyrrolidinyl- imparts specific stereochemical characteristics that can influence its interactions with biological targets. The enantiomeric purity of this compound is crucial for its pharmacological properties, as small differences in stereochemistry can lead to significant variations in efficacy and safety profiles. Recent advancements in chiral synthesis techniques have enabled the efficient and scalable production of this compound, making it more accessible for both academic and industrial research.

In the context of medicinal chemistry, Morpholine, 4-(3S)-3-pyrrolidinyl- has been explored for its potential as a lead compound in the development of novel therapeutic agents. Studies have shown that this compound exhibits promising activity against various targets, including enzymes, receptors, and ion channels. For instance, research published in the Journal of Medicinal Chemistry highlighted the ability of Morpholine, 4-(3S)-3-pyrrolidinyl- to modulate G protein-coupled receptors (GPCRs), which are key targets for a wide range of diseases such as cardiovascular disorders, neurological conditions, and metabolic syndromes.

One of the notable applications of Morpholine, 4-(3S)-3-pyrrolidinyl- is in the field of neuropharmacology. Preclinical studies have demonstrated that this compound can cross the blood-brain barrier and exert neuroprotective effects. These findings suggest its potential use in treating neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Additionally, Morpholine, 4-(3S)-3-pyrrolidinyl- has been investigated for its anti-inflammatory properties, which could be beneficial in managing chronic inflammatory conditions.

From a pharmaceutical development perspective, Morpholine, 4-(3S)-3-pyrrolidinyl- has shown favorable pharmacokinetic properties. Its stability under physiological conditions and low toxicity profile make it an attractive candidate for further optimization and clinical evaluation. Ongoing clinical trials are aimed at assessing the safety and efficacy of this compound in human subjects, with preliminary results indicating promising outcomes.

Moreover, the versatility of Morpholine, 4-(3S)-3-pyrrolidinyl- extends beyond its direct therapeutic applications. It serves as a valuable intermediate in the synthesis of more complex molecules with diverse biological activities. For example, it has been used as a key building block in the development of small molecule inhibitors targeting specific protein-protein interactions (PPIs), which are increasingly recognized as important therapeutic targets in cancer and other diseases.

In conclusion, Morpholine, 4-(3S)-3-pyrrolidinyl- (CAS No. 216669-67-9) is a multifaceted compound with significant potential in various areas of biomedical research. Its unique structural features and favorable biological properties make it an important molecule for further investigation and development. As research continues to uncover new insights into its mechanisms of action and therapeutic applications, Morpholine, 4-(3S)-3-pyrrolidinyl- is poised to play a crucial role in advancing our understanding and treatment of complex diseases.

• 78844-83-4(Morpholine, 4,4'-(1-hexyl-1,2-ethanediyl)bis-)
• 1181264-99-2(1-[2-(morpholin-4-yl)ethyl]pyrrolidin-3-amine)
• 53617-37-1(4-(Pyrrolidin-3-yl)morpholine)
• 84466-86-4((S)-4-[(1-METHYL-2-PYRROLIDINYL)METHYL]MORPHOLINE)
• 953888-69-2(2-(morpholin-4-yl)butan-1-amine)
• 511295-99-1(Morpholine, 4-[(2R)-2-pyrrolidinylmethyl]-)
• 1219979-89-1(4-(3-Pyrrolidinyl)morpholine dihydrochloride)
• 511295-94-6(Morpholine,4-(3R)-3-pyrrolidinyl-)
• 215503-90-5(4-(2-Pyrrolidinylmethyl)-morpholine 2hcl)
• 91790-91-9((s)-4-(2-Pyrrolidinylmethyl)morpholine 2hcl)